purchase

product

Xeris Biopharma Holdings Inc

manipulation

$XERS  This stock has become totally distorted by Wall Street manipulators!

In fact its just market manipulation by  shorts and rich assholes who use stocks like slot machines.

$XERS This stock is heavily MANIPULATED by a &quot;Gang of Shortsellers&quot; and has nothing to do with a fair market price!

It is so obvious this is being systematically walked down (manipulated) and has nothing to do with the Company itself, products, or the overall market.

Just goes to show how badly manipulated this is.

The manipulation of these criminals is unbelievable.

price

This Share Price is still 
 
Crazy  
 
Stupid  
 
Low. Cheers!

$XERS  This share price is crazy stupid low.

You’d think Paul would have some shame being below their price.

What is most disappointing about XERS, except for the collapse in stock price, is the failure of management to do much of anything to encourage retail or institutional investors to continue to have the confidence in management of the company or its future.

I think price targets are fake… there compensated to make targets IMO.

suck

Unfortunately, the mkt sucks now and that’s reflected in sp.

The whole market sucks and this has been unjustly hammered.

$XERS this is so fucked up its unbelievable.

Invested a lot of money , and realizing we are fucked.

market

What a crappy market! Hopefully next week will be better:)

$XERS A bad market must admit it is really a bad day.

$XERS A 10+ cent drop when you only have 14 of those until 0 ahead of all that gobbledygook fundamental longs are spouting is not a great sign of market confidence.

$XERS market on a year and this lame duck is flat or sinking

but unfortunately, in this market, not cheap either, and even less an outright buy without a very very strong conviction.

Market hinting something is terribly wrong with this company.

revenue

$XERS High risk is an understatement with XERS, weak drug lineup, weak pipeline, revenue grow slowing, cash burn increasing and worse than weak management should tell you to stay away.

Nothing positive, revenue continues to slow, spending increasing, generics coming, recorlev under performing and most important, incompetent management! !

Personally, I think this is very conservative, and comes in below the Strongbridge &quot;Low Case&quot; from page 87 of the merger prospectus because it comes out to $172M annual revenue in 2023 compared to $216M revenue on the prospectus.

Revenues are slowing, expenses are increasing, tech is marginal, patents will be expiring, pipeline is horrible and management is horrible.

but also very disappointing that my EV charger stocks have $Billion mkt caps with less than $50M revenue and years from cash flow positive and yet.

Not only are the current drugs low revenue producers and the pipeline is horrible.

.WS not impressed with 3 low revenue drugs and weak pipeline.

$XERS  By the way, I think the lack of insider purchases is good news.

$XERS their primary product increases 9% week to week sales with an overall trend that&#39;s incredible.

$XERS I like their products and the inject opportunity with Horizon Tepezza is huge I wish they weren&#39;t acquired so they can keep a focus on that.

Earnings are growing and there could be great news any day from a variety of sources, whether a collab exercise of option, new product collab, royalty pmt, etc.

More important is that they grow Recorlev&#39;s revenue at high(er) speed, and continue to gain market share with Gvoke without product price drop.

Revenue exploding on the upside with
their 4 products.

Even if they have more short term gains coming soon, we know the Gvoke product will gain share back due to the more pleasant experience. Patience.

Gvoke is the best and easiest product out there.

Products have been approved and much more is coming, wait and relax.

For a tiny company like xeris to go toe to toe with lilly and grow share shows they have the best product.

$XERS Truly so strange, everything Xeris had in its programme has been met, briefly 3 FDA approved products, collaborations with major pharmacies and much, much more.

Two other drugs, each growing revenue steadily.

That said, I fully expect continuing  script and revenue growth, upcoming cashflow breakeven and some nice juicy licensing deals to resolve that in the months ahead.

Two (2) other drugs, each growing revenue steadily.

There is so much good news here, growing revenue, a stable base, conservative management, and connections to big pharma.

drug

A levothyroxine formulation that looks positive (most commonly prescribed drug) A full proven technology platform to deliver hard to administer drugs by a simple injection.

We have other amazing drugs, Recorlev, Gvoke and more including some drugs yet to be approved.

$XERS Good market yesterday, looking good today and good old XERS continues in the tank!!

but all of last week, in the middle of heavy market turmoil where we normally go down heavily, we stayed up and rose. Why?

Plenty of small caps were brought to lows (and thus made good buys) before starting recovery in this bear market, $ADMA, $ARAY, $PRTK, $CDTX, they all have turned or are turning around cause there is deep value and a clear path to profitability.

SCWorx Corp

pump-and-dump

$WORX This is an example of a shitco stock that is subject to a Pump &amp; Dump scheme every 3-6 months (which never lasts).

$WORX Shorts will lose the battle and the war.

wall

short

$WORX Shorts are bagged spreading erroneous and unfounded nonsense.

$WORX is consistent with good PR, new contracts, new products and stock purchase deals with institutional investors!

The new product offering enables hospitals of all sizes to quickly and easily benefit from the SCWorx data platform.

New products and a chart with mega upside. 🚀

$WORX Business booming with more clients new products and a chart bottomed ready to go 🚨🚨🚨❗️💎 a gem

play

$IVDA  $WORX has potential for play of the month even year with a set up like this.

Now i am calling $WORX - huge 13g and bottomed chart, this will be the next big undervalue play.

$WORX The unequivocal top technology play for hospitals and medical purposes.

$WORX HOD break out in play 👀🚨🚨🚨🔜

$WORX 💎This is my favorite play right now by far, i am swinging for big gains.💎 
 
$CMPO 18% short!

float

insider

The price action is of a winner 🚨🚨🚨🚀👀
$WORX Insiders been loading.

Anavex Life Sciences Corporation

wait

Seems crazy to me to unjust approvals that are going on while we wait on legitimate results!!!

But why wait 3 years with that when Anavex 50mg dose is likely better! !

So, if one waits months for an answer and then has to resubmit to another journal it can hold things up.

This is a shitshow till data is presented.

loss

but  losses  and  disappointment  with  Missling.

$AVXL Took my $250 loss and Got out guys too much noise not enough action.

but was faked by the move and held them to expiration and had to book a loss of $19,000.

shareholder

The krout has proven to be an a hole toward shareholders.

Missling is a greedy pig, doesnt see the bad he does by delaying intentionally, not only to shareholders,

i am telling for years that we need to fire that shitty guy just here to full his pockets without any consideration for his shareholders.

.this guy doesnt respect his shareholders and he must be sue for that.

$AVXL fire Missling, he has been here 9 years and done nothing to drive shareholder value other than BS hype

$AVXL why does the company not believe they are beholden to their shareholders?

$AVXL Unfortunately the Investorshub AVXL board has deteriorated to the point that it is basically a board consisting of almost entirely FUD with almost more bashers than true shareholders.

Messling is grossly deficient in anticipating the expectations of shareholders and the market.

$AVXL as corporate shareholder, I have sent an email on dec. 21st and a friendly reminder yesterday to IR - no response yet !!

One hand he says he care for shareholder value, on other hand he is purposely not sharing updates.

shareprice

$AVXL missling next time should change a few letters when hiring and SP will improve: from FDA to FBI former employee.

$AVXL Every time Missling speaks, the SP tanks…..amateurish communication, unbelievable.

It&#39;s stupid, it wastes time (and $$$) and it leaves the company vulnerable with a supressed SP.

Based on Rett alone, SP is well under 100$, sorry to bust your ballown,but please try to stay realist and keep a little credibility!

$AVXL The sp is wrong there must be a glitch

$AVXL not that i am happy with the SP overall

$AVXL Until you realize that and admit that the presenter screwed up in rushing the presentation the SP will stay where it’s at

$AVXL wandering when we will cross ANVS SP ;) 
never again!!!!

$AVXL we didnt cross ANVS SP yet, no good haha!

show

Take your money from this shit show and deposit in your bank account.

What an absolute unregulated criminal shit show this market has become.

Missling shows poor judgement and is not suited to be ceo.

SHOWS THE EXTREME WEAKNESS AND  DISTRESS THE STOCK IS UNDER.

but need more time to evaluate and announce a conference call for Monday instead we have a shit show.

Can’t ask for too much better of a purchase price now.

They have a great product treating cancer with immunotherapy, peer reviewed journal

look into Adamis Pharma, no more speculation, now it&#39;s real, two FDA approved meds, two major products, top of the line in comparison of their rivals, for cheaper price, AND WITH NO MUCH COMPETITION!

2023  is  going  to  be  very  positive  for  patients  of  our  products  and  shareholders  alike

Their product works (see the mad Pole Piotr’s graphs 😵‍💫)
Multi year holds, the bodadem.

We have great data out of a superior product,

They have good products and a solid future.

business-result

Anavex&#39;s A2-73 Blarcamesine&#39;s trial results on 2 previously completed adult phase-3 trials were highly successful.

But the company actually has never seen before wonderful results.

If results hold up, the stock will achieve massive gains.

The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.

Alzheimer&#39;s is the most valuable and most difficult indication and most desired lately..  and only Anavex really has some great results with a great safety record. .

The  sava  results  trounce  you  guys  🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

Sava has potential and the phase 3 results will show the truth.

- Timo grimmer is in the team 
- All endpoints of the clinical trial were reached 
 
I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.

we have a drug, even many drugs, good for so many indications,  to become a giant pharma, we are about to get billions in revenues.

$AVXL The improvements in the drug arm cannot be lucky. .

I&#39;m looking forward to seeing the long term AD data on ANVS and have the feeling it&#39;s going to end up being the best in class AD treatment as well.

Do not listen to any FUD this drug is the real deal.

$AVXL amazing to see the actual benefits to people and their families of this “miracle drug” as they call it

$AVXL Dr. Perry said we have a legendary drug which actually reverses AD and is safe unlike Adulhelm.

trial

$AVXL amazing  avxl  still  in  singke  digits  after  a  supposedly  amazing  “pivotal”  trial  readout  🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

$AVXL The trial met both co-primary and secondary endpoints showing statistically significant reduction of clinical decline as measured by those endpoints.

$AVXL Australia trial data meets the gold standard.

2-73 has orphan designation for Rett which combined with the multiple Rett trials and it very good safety record should make it a great candidate for AA.

This company has yet to fail to meet endpoints on any trial and the thousands of papers on the MOA  eliminates fraud with science, and the company is in great fiscal shape so no shenanigans there.

Top Stocks matching your search for "purchase products"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

XERS

Xeris Biopharma Holdings Inc

15.52%

$1.16 - $1.34

Nov, 18, 2022

Nov, 16, 2022

WORX

SCWorx Corp

-25.75%

$0.44 - $0.33

Dec, 5, 2022

Divihomes is Now Live

AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Mar, 13, 2023

Nov, 30, 2022

XERS

Xeris Biopharma Holdings Inc

15.52%

$1.16 - $1.34

Nov, 18, 2022

Nov, 16, 2022

WORX

SCWorx Corp

-25.75%

$0.44 - $0.33

Dec, 5, 2022

AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Mar, 13, 2023

Nov, 30, 2022